Should drug companies be allowed to sponsor Cochrane reviews?

Moynihan, Ray
November 2003
CMAJ: Canadian Medical Association Journal;11/25/2003, Vol. 169 Issue 11, p1201
Academic Journal
Reports on the launch of an international debate by Cochrane Collaboration about whether to embrace sponsorship from private industry in October 2003. Impact of drug company sponsorship on the systematic reviews of therapies being conducted by the group; Possible source of financing aside from private drug companies.


Related Articles

  • Taking Control of Your Quality Control. Rodrigues, George // BioPharm International;Jul2006, Vol. 19 Issue 7, p40 

    The article focuses on the mandate of the U.S. Food and Drug Administration that laboratories should incorporate quality control processes to help ensure the safety, purity, and effectiveness of therapeutics samples. The author points out that the federal regulations for quality control...

  • ExonHit Therapeutics reports positive data from Phase IIa Alzheimer's trial.  // PharmaWatch: CNS;Nov2009, Vol. 8 Issue 11, p5 

    The article reports on the results of the clinical data of pharmaceutical company ExonHit Therapeutics Inc. The data demonstrates that EHT 0202, ExonHit's lead candidate for the treatment of Alzheimer's disease, is a safe and generally well tolerated in patients. Details on the objectives of the...

  • Pipeline preview.  // Formulary;May2006, Vol. 41 Issue 5, p213 

    The article introduces several products in the pharmaceutical industry. Among the new drugs are Sitaxsentan, to be marketed as Thelin by Encysive Pharmaceuticals, PTC124 (PTC Therapeutics) for Duchenne muscular dystrophy, and Amphotericin B with a trademark SinuNase of Accentia...

  • Research Update.  // PharmaWatch: Biotechnology;Apr2006, Vol. 5 Issue 4, p9 

    The article offers news briefs in the pharmaceutical industry in 2006. Peregrine Pharmaceuticals Inc. has completed its planned patient enrollment and dosing for its initial phase I clinical trial for Tarvacin, an anti-viral treatment for chronic hepatitis C virus infection. Critical...

  • Phase III Failures: What Can Be Done? Beltangady, Mohan // Applied Clinical Trials;Sep2005, Vol. 14 Issue 9, p82 

    Looks at what can be done to prevent failures in Phase III clinical trials. Increasing costs of drug development; Possible reasons for why Phase III trials may fail to confirm what has been learned from Phase II studies; Value of flexible trial designs.

  • How Do Pharmaceutical Companies Approach Data from Sexual Health Studies for Regulatory Agencies? Dilleen, Maria; Haughie, Scott // Annual Review of Sex Research;2005, Vol. 16 Issue 1, p53 

    The article outlines the importance of statistical input into clinical trial research in the pharmaceutical industry an in interactions with regulatory agencies. It focuses on the role of statisticians in projects on sexual health during the 2nd and 3rd phases of clinical trials that are...

  • Randomized clinical trials: Slow death by a thousand unnecessary policies? Ferris, Lorraine E.; Naylor, C. David // CMAJ: Canadian Medical Association Journal;10/12/2004, Vol. 171 Issue 8, p892 

    Focuses on financial conflicts of interest between researchers and industry sponsors in conducting clinical trials. Roles of researchers in clinical trials; Purpose of pharmaceutical companies in conducting their own clinical trials; Susceptibility of preapproval studies by pharmaceutical...

  • Engaging Tomorrow's Volunteers Through Museum Learning. Getz, Kenneth A. // Applied Clinical Trials;Jun/Jul2014, Vol. 23 Issue 6/7, p18 

    The article discusses the efforts to provide outreach and education to inform patients and the public about the clinical research process. The author reveals that the National and international polls conducted by the Center for Information and Study on Clinical Research Participation (CISCRP)...

  • PER-PATIENT COSTS CLIMB THROUGH CLINICAL TRIAL.  // Biotech Business;May2013, Vol. 26 Issue 5, p6 

    The article discusses a study on the correlation between patient enrollment and total cost as depicted in the Cutting Edge Information study. It provides an overview of the study involving the phase 1, 2 and 3 of the clinical trials and its average total cost. It also highlights the latest...

  • Clinical Trials Registration Efforts Gain Some Ground. Zielinski, Sarah L. // JNCI: Journal of the National Cancer Institute;3/16/2005, Vol. 97 Issue 6, p410 

    Reports on the progress in clinical trials registration efforts in the U.S. Support of the pharmaceutical industry to several principles of clinical trials registration; Efforts of the World Health Organization to standardize information collected in clinical trial registries.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics